<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476229</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0892</org_study_id>
    <nct_id>NCT00476229</nct_id>
  </id_info>
  <brief_title>Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies</brief_title>
  <official_title>Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      1. To determine whether the primary endpoint: the composite success rate, defined as the&#xD;
      proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host&#xD;
      Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have&#xD;
      engrafted, is likely to be at least 40%.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To determine the cumulative incidence of chronic graft versus host disease.&#xD;
&#xD;
        2. To determine the overall and disease free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of drugs used for this study will help to weaken your immune system, which&#xD;
      may help to allow the donor's blood stem cells to engraft (grow) in your body.&#xD;
&#xD;
      Anti-thymocyte globulin (also called ATG or thymoglobulin) is designed to help reduce the&#xD;
      risk of transplant rejection and to help prevent graft versus host disease.&#xD;
&#xD;
      Rituximab is designed to attach to lymphoma cells, which may cause them to die.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be admitted to the&#xD;
      hospital 12 days before the blood stem cell transplant (BSCT), in order to start the&#xD;
      pre-transplant treatments and testing. You will have blood (about 1 tablespoon) drawn for&#xD;
      routine tests every day while you are in the hospital (before and after the transplant).&#xD;
      After the transplant, this blood will be used to check the status of the transplant and watch&#xD;
      for any side effects.&#xD;
&#xD;
      You will receive radiation therapy (total lymphoid irradiation) for a total of 10 days before&#xD;
      the planned transplant. Radiation therapy will not be given on the weekends. The last&#xD;
      radiation treatment will be on the morning of the day you receive your stem cell transplant.&#xD;
&#xD;
      For a total of 5 days after admission to the hospital, you will also receive ATG. ATG will be&#xD;
      given through a catheter (plastic tube) that is placed into the large chest vein. The&#xD;
      catheter (called a central venous catheter) will stay in place throughout treatment.&#xD;
&#xD;
      You will receive certain drugs as premedication to try to prevent an allergic reaction to the&#xD;
      ATG. These may include drugs like acetaminophen (Tylenol), diphenhydramine (Benadryl), and/or&#xD;
      steroids which may include solumedrol or prednisone. Tylenol is given by mouth, and Benadryl&#xD;
      and steroids are given either by vein (over 10-15 minutes) or by mouth.&#xD;
&#xD;
      The combination of ATG and radiation will weaken your immune system. A weakened immune system&#xD;
      may help to allow your body to &quot;accept&quot; donor cells, and it may decrease the chance of your&#xD;
      body rejecting the cells.&#xD;
&#xD;
      If your diagnostic biopsy showed that a certain protein was found on your tumor cells, you&#xD;
      may also receive rituximab therapy. If you are eligible for rituximab treatment, you will&#xD;
      receive the drug once a week for 4 weeks. You will receive rituximab through the central&#xD;
      venous catheter or through a vein over 6-8 hours. The first dose will be given on an&#xD;
      outpatient basis at 13 days before the stem cell transplant. The next 3 doses may be given in&#xD;
      the hospital or on an outpatient basis. You will receive rituximab 6 days before the&#xD;
      transplant, and then 1 and 8 days after the transplant. Tylenol and steroids will be given&#xD;
      before the rituximab to try to prevent an allergic reaction.&#xD;
&#xD;
      You will be given tacrolimus to try to prevent graft versus host disease (when the donor's&#xD;
      immune cells react against the recipient's body, attacking the recipient's cells and&#xD;
      tissues). You will receive tacrolimus either through the central venous catheter (over 24&#xD;
      hours each time) or by mouth starting 3 days before the stem cell transplant. You will&#xD;
      continue receiving tacrolimus as long as your doctor feels it is necessary, which could be&#xD;
      anywhere from about 3 months to several years. This will depend on factors such as whether or&#xD;
      not you have graft versus host disease, how many donor cells are in your blood, and the&#xD;
      status of your disease.&#xD;
&#xD;
      Cellcept (MMF) will also be given to try to prevent graft versus host disease, starting 1 day&#xD;
      after the transplant and continuing through Days 28-42 after the transplant. The MMF will be&#xD;
      given twice a day through the central venous catheter over 2 hours, or by mouth.&#xD;
&#xD;
      After the pre-transplant treatments and testing are finished, you will have the blood stem&#xD;
      cell transplant. Blood stem cells from a donor will be infused over about 1 hour through your&#xD;
      central venous catheter. This can be done while you are in the hospital or on an outpatient&#xD;
      basis at M. D. Anderson. Steroids and Benadryl will be given through the catheter before the&#xD;
      stem cell transplant to try to prevent an allergic reaction. The catheter will be removed&#xD;
      once you no longer need to be given fluids, blood products, and other treatments through the&#xD;
      catheter for graft versus host disease. This may take anywhere from 3 months after the&#xD;
      transplant to several years.&#xD;
&#xD;
      You will have additional blood (about 2 tablespoons) drawn, bone marrow aspirations and&#xD;
      biopsies, chest CT scans, and/or chest x-rays performed as needed to check the effects of the&#xD;
      transplant. You will have transfusions of blood and platelets as needed, and you will have to&#xD;
      sign a separate consent document for these transfusions.&#xD;
&#xD;
      Blood (about 1 tablespoon each time) will also be drawn at least 2-3 times a week for at&#xD;
      least 100 days after the transplant, or longer if the study doctor feels it is necessary.&#xD;
&#xD;
      Treatment will be given in the hospital or an outpatient basis at M. D. Anderson. You may&#xD;
      need to stay in the hospital for 3-4 weeks. You will be taken off the study if your disease&#xD;
      gets worse.&#xD;
&#xD;
      This is an investigational study. The FDA has approved the drugs used in this study. Their&#xD;
      use together in this study is investigational. Up to 40 patients will take part in this&#xD;
      study. All will be enrolled at M. D. Anderson Cancer Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Success Rate</measure>
    <time_frame>Baseline to Day 100, assessment at Day 100</time_frame>
    <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>1.5 mg/kg by vein on Days -11 to -7.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Lymphoid Irradiation</intervention_name>
    <description>80 cGy daily on days -11 to -7 and -4 to 0.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>TLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Infusion</intervention_name>
    <description>PBSC infusion administered on day 0.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Blood Stem Cell Transplant</other_name>
    <other_name>BSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 by vein on days -13, -6, 1, &amp; 8. Only those patients whose tumors express CD20 will receive Rituximab.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age up to 70 years.&#xD;
&#xD;
          -  Patients with lymphoid malignancies (primary refractory or recurrent) beyond first&#xD;
             remission or unresponsive to therapy and not eligible for protocols of higher&#xD;
             priority. Patients should have had at least a partial remission or have stable disease&#xD;
             with prior chemotherapy. Patients with bulky disease (greatest dimension &gt; 5 cm by&#xD;
             radiographic or clinical examination are not eligible).&#xD;
&#xD;
          -  Adequate renal function, as defined by serum creatinine &lt;1.8 mg/dL.&#xD;
&#xD;
          -  Adequate hepatic function, as defined by SGPT &lt;3 times upper limit of normal; serum&#xD;
             bilirubin and alkaline phosphatase &lt;3 times upper limit of normal.&#xD;
&#xD;
          -  Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced&#xD;
             vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) &gt;35% of expected&#xD;
             corrected for hemoglobin. Exceptions may be allowed for patients with pulmonary&#xD;
             involvement after discussing with Principal Investigator.&#xD;
&#xD;
          -  Adequate cardiac function with left ventricular ejection fraction &gt;35%. No&#xD;
             uncontrolled arrhythmias or symptomatic cardiac disease.&#xD;
&#xD;
          -  Zubrod performance status &lt;2&#xD;
&#xD;
          -  Patients must have an human leukocyte antigens (HLA) matched, or one A, B, C, DR, or&#xD;
             DQ mismatched related or unrelated donor (by high resolution typing). Donor must be&#xD;
             willing to donate peripheral blood progenitor cells.&#xD;
&#xD;
          -  Patient should be willing to participate in the study by providing written consent.&#xD;
&#xD;
          -  Negative beta human chorionic gonadotrophin (hCG) test in a woman of child bearing&#xD;
             potential (defined as not post menopausal for 12 months or no previous surgical&#xD;
             sterilization).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) disease.&#xD;
&#xD;
          -  Evidence of acute or chronic active hepatitis or cirrhosis.&#xD;
&#xD;
          -  Uncontrolled infection, including Hepatitis B, C, Human immunodeficiency virus (HIV)&#xD;
             or human T-cell lymphotropic virus type 1 (HTLV-1) infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chitra M. Hosing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>July 13, 2011</results_first_submitted>
  <results_first_submitted_qc>July 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>Total Lymphoid Irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 14, 2006 to October 15, 2008. All patients were registered at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive shortness of breath</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Success Rate</title>
        <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
        <time_frame>Baseline to Day 100, assessment at Day 100</time_frame>
        <population>Analysis was per protocol. One participant was inevaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiation + Chemotherapy + BSCT</title>
            <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Success Rate</title>
          <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
          <population>Analysis was per protocol. One participant was inevaluable.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alive at 100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 year, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased bilrubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>low blood pressure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dysrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>arterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other cardiac</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pericardial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>other endocrine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <description>abdominal</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other general disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased ALT</sub_title>
                <description>Alanine aminotransferase (ALT or SGPT)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased biblrubin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased LDH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypermagesium</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>metabolic other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other neruologic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>neurologic mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>skin other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to financial support.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chitra M. Hosing, MD/Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>gmccormi@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

